TFDA-2024-0031-V031
Major variation for application TFDA-2024-0031. Major variation: New Dosage Strength for Kcluximab — critical change
Variation Number
TFDA-2024-0031-V031
Type
Major
Application
Change
Status
Completed
Fee
€52,919
Submitted
2023-06-16
Approved
—
Description
Major variation: New Dosage Strength for Kcluximab — critical change